LAP3抗体;LAP3 Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of LAP3 expression in 293T cell lysate.    

  
  

The LAP3 antibody targets leucine aminopeptidase 3 (LAP3), a zinc-dependent metallopeptidase belonging to the M1 family of aminopeptidases. LAP3. also known as cystinyl aminopeptidase or insulin-regulated aminopeptidase (IRAP), plays a critical role in processing bioactive peptides, including angiotensin III, oxytocin, and vasopressin, by cleaving N-terminal amino acids. It is widely expressed in tissues, particularly in the brain, placenta, and muscle, and is notably associated with intracellular vesicles, including GLUT4 storage compartments in adipocytes and myocytes.

LAP3 has garnered attention for its dual roles in physiological and pathological processes. It regulates blood pressure, fluid balance, and uterine contractility through peptide metabolism. Additionally, LAP3 is implicated in cognitive functions, as it modulates synaptic plasticity and memory by interacting with neurotransmitter systems. In cancer research, LAP3 overexpression has been observed in certain tumors, where it may influence cell proliferation, invasion, and drug resistance.

Antibodies against LAP3 are essential tools for studying its expression, localization, and enzymatic activity. They enable applications such as Western blotting, immunohistochemistry, and functional assays to explore LAP3's involvement in diseases like hypertension, Alzheimer’s disease, and cancer. Recent studies also highlight its potential as a therapeutic target or biomarker, driving the development of selective inhibitors or diagnostic probes. Overall, LAP3 antibodies contribute to unraveling the enzyme's multifaceted biological and clinical significance.